Hangzhou, China and Ahmedabad, India – September 3, 2026:

Tigermed and Veeda Lifesciences – two global contract research organizations (CROs) rooted in China and India, respectively – announced a strategic alliance to create a unified China-India clinical research corridor. This collaboration provides global pharmaceutical and biotechnology sponsors with a seamless platform to conduct global clinical trials anchored across both countries through a single contract and point of accountability – a powerful springboard into the global drug development environment.

By combining their complementary strengths, Tigermed and Veeda deliver an advantage no single-country CRO can match. Global sponsors gain access to the world’s two largest clinical research populations, offering unparalleled scale, genetic diversity, and cost efficiency for multi-regional trials. Sponsors can now access both markets through a single point of accountability, with coordinated trial designs, harmonised data standards, and unified project governance, significantly accelerating study start-up and enrolment timelines across multiple geographies.

Quality and compliance are the alliance’s foundation. The combined infrastructure framework - spanning Tigermed’s network of ICH-GCP compliant 1500+ trial sites across China and Veeda’s USFDA, EMA, and India’s CDSCO compliant bioavailability, bioequivalence, and Phase I–IV capabilities in India – gives sponsors access to large, genetically diverse, treatment-naïve patient populations, improving statistical robustness for concurrent global regulatory submissions and accelerating enrolment for multi-regional clinical trials.

The Tigermed-Veeda alliance unites Veeda’s four service pillars (Clinical Trials, Biopharma Services, BA/BE and Phase-I Services, and Preclinical Research) with Tigermed’s corresponding offerings. Sponsors can conduct everything from early bioanalytical assays and GLP toxicology to Phase I–IV trials and specialty lab services under one roof across China and India. Both partner organizations –Tigermed and Veeda - are aligning their digital platforms and AI-enabled, real intelligence-led systems to further enhance trial efficiency. For international clients, this unified platform serves as an “engine room” to deliver studies reaching patients worldwide.

“This alliance is a statement about the future of clinical research — one where the India–China corridor becomes a defining axis of global drug development. Together with Tigermed, we are building a platform that gives sponsors speed, quality, and scale without compromise.”

— Mr. Binoy Gardi, Founder, Group CEO and MD, Veeda Lifesciences

“We are delighted to partner with Veeda to offer global clients a truly seamless research experience across China and India. By combining Tigermed’s extensive China presence with Veeda’s renowned capabilities in India, sponsors gain an unparalleled advantage — the ability to run multi-country trials through one high-quality, harmonised provider. This new and unique model of client-centric delivery will accelerate innovation and benefit patients worldwide.”

— Zengyu “Michael” Wen, Co-President, Tigermed Group

“The unique synergies that the alliance between Tigermed and Veeda creates position this partnership at the forefront of an increasingly dynamic global research paradigm. Bringing Chinese innovation and science — today delivering more clinical research than any other country in the world — together with India’s vast capabilities and ambition, this alliance offers science, capacity, and proven quality, whilst remaining highly competitive. Having had the pleasure of working for Tigermed and now the honour of leading Veeda Lifesciences’ global clinical trials business, I am genuinely excited to support the next chapter for both organisations as we grow forward, building on our core capabilities in AI-enabled, real intelligence-led clinical research. The foundation of our shared beliefs and values — in the patient, our people, and the clients we serve — creates the fertile ground on which this partnership will continue to grow.”

— Mr. James Brook, Chief Operating Officer – Global Clinical Trials, Veeda Lifesciences

Mr. Brook previously served as Regional Head of EMEA at Tigermed Group, where he led the expansion of Tigermed’s international clinical trial business.

Being headquartered in China and India respectively, Tigermed and Veeda have individually evolved into truly global CROs capable of serving sponsors worldwide. Tigermed operates in over 180 locations with 10,000+ employees, while Veeda’s multi-regional network spans more than 26 countries. Together, they form a single coordinated gateway — using the India–China corridor as a springboard for sponsors to conduct clinical development on a global scale.

About Tigermed:

Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 4,200 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 11,900 employees across Asia Pacific, Europe, North America, Latin America and Africa. We are devoted to building an integrated platform that enables the boundless possibilities for the healthcare industry, embracing challenges to fulfill our commitment to addressing patients’ unmet medical needs, and ultimately saving lives.

About Veeda Lifesciences:

Veeda Lifesciences is a global contract research organization (CRO) headquartered in Ahmedabad, India, offering full-service and functional support across the entire drug development lifecycle – from preclinical research and bioanalytical services to clinical pharmacology and all phases of clinical trials (Phase I–IV). With operations in multiple countries and trials across 26 geographies, Veeda combines global reach with local expertise to support pharmaceutical and biotechnology clients. Renowned for its scientific excellence, regulatory compliance, and quality-driven approach, Veeda continuously invests in its people, technology, and AI-enabled platforms to accelerate development of innovative therapies and high-quality generic medicines, ultimately improving patient outcomes worldwide.